MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.54
+1.63
+3.47%
After Hours: 48.54 0 0.00% 16:00 09/17 EDT
OPEN
46.90
PREV CLOSE
46.91
HIGH
48.75
LOW
46.34
VOLUME
392.15K
TURNOVER
--
52 WEEK HIGH
82.49
52 WEEK LOW
21.98
MARKET CAP
1.84B
P/E (TTM)
-17.6824
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of QURE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

QURE News

  • New coverage - healthcare
  • Seeking Alpha - Article.5d ago
  • Mizuho Initiates Coverage On uniQure with Buy Rating, Announces $67 Price Target
  • Benzinga.5d ago
  • uniQure prices stock offering at $46; shares down 2% premarket
  • seekingalpha.09/06 15:30
  • 16 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.09/06 12:31

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About QURE

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
More

Webull offers Uniqure NV (QURE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.